About: Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19
Creator	Ewings, Sean Poole, Stephen Brendish, Nathan Clark, Tristan Mansbridge, Christopher Naidu, Vasanth Norton, Nicholas Presland, Laura Wheeler, Helen
Source	Elsevier; Medline; PMC
abstract	INTRODUCTION: Management of the COVID-19 pandemic is hampered by long delays associated with centralised laboratory PCR testing. In hospitals this leads to poor patient flow and nosocomial transmission and so rapid, accurate diagnostic tests are urgently required. The FebriDx is a point-of-care test that detects an antiviral host response protein in finger prick blood within 10 minutes, but its accuracy for the identification of COVID-19 is unknown. METHODS: We performed a real-world diagnostic accuracy study of FebriDx in hospitalised patients during the first wave of the pandemic. Measures of diagnostic accuracy were calculated based on FebriDx results compared to the reference standard of SARS-CoV-2 PCR on combined nose and throat swabs. A multivariable predictive model including FebriDx, age, sex, and clinical characteristics was developed and underwent internal validation. RESULTS: FebriDx was performed on 251 patients and gave a valid result in 248. 118 of 248 (48%) were PCR positive for COVID-19. FebriDx results were available after 10 minutes compared with 1.7 (1.6 to 2.1) hours with point-of-care PCR testing and 23.4 (17.2 to 31.1) hours with laboratory PCR testing. Sensitivity of FebriDx for the identification of COVID-19 was 93% (110/118; 95% CI 87 to 97%) and specificity was 86% (112/130; 95%CI 79 to 92%). Positive and negative likelihood ratios were 6.73 (95%CI 4.37 to 10.37) and 0.08 (95%CI 0.04 to 0.15) respectively. In the multivariate model age, sex and other clinical features did not contribute significantly to the effect of the FebriDx result in distinguishing patients with and without COVID-19. CONCLUSIONS: During the first wave of the pandemic, FebriDx had high accuracy for the identification of COVID-19 in hospitalised adults and could be deployed as a front door triage tool. TRIAL REGISTRATION: ISRCTN14966673
has issue date	2020-06-21(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2020.06.051
bibo:pmid	32579983
has license	no-cc
sha1sum (hex)	4a51b31dcbfffccdc204420e8050dc158982e13d
schema:url	https://doi.org/10.1016/j.jinf.2020.06.051
resource representing a document's title	Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19
has PubMed Central identifier	PMC7306108
has PubMed identifier	32579983
schema:publication	J Infect
resource representing a document's body	covid:4a51b31dcbfffccdc204420e8050dc158982e13d#body_text
is schema:about of	named entity 'RNA' named entity 'POCT' named entity 'diagnostic accuracy' named entity 'PCR testing' named entity '85%' named entity 'PCR' named entity 'PCR' named entity 'symptom' named entity 'COVID' named entity 'sensitivity, specificity' named entity 'COVID' named entity '95% CI' named entity 'NPV' named entity 'SARS-CoV-2' named entity 'infection' named entity 'viral RNA' named entity 'nose and throat' named entity 'MxA' named entity 'disease prevalence' named entity 'COVID' named entity 'case report form' named entity 'Diagnostic accuracy' named entity 'White British' named entity 'PCR' named entity 'host response' named entity 'PCR' named entity 'COVID' named entity 'viruses' named entity 'healthcare systems' named entity 'COVID-19' named entity 'Bayesian Information Criterion' named entity 'COVID-19' named entity 'MxA' named entity 'COVID-19' named entity 'confidence interval' named entity 'COVID' named entity 'immunocompetent' named entity 'interferon' named entity 'PPV' named entity 'COVID-19' named entity 'asymptomatic' named entity 'PCR' named entity 'anosmia' named entity '95% CI' named entity 'RNA' named entity 'blood clotting' named entity 'COVID' named entity 'MxA' named entity 'positive and negative predictive values' named entity 'PCR testing' named entity 'MxA' named entity 'sample size' named entity 'COVID' named entity 'diagnostic accuracy' named entity 'urgent care' named entity 'pneumonia' named entity 'missing data' named entity 'secondary care' named entity 'COVID-19' named entity 'acute hospitals' named entity 'area under the curve' named entity 'COVID-19' named entity 'influenza' named entity 'PPV' named entity 'COVID-19' named entity 'Influenza' named entity 'host response' named entity 'PCR' named entity 'sensitivity, specificity' named entity '95% CI' named entity 'host response' named entity 'NPV' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software